Developer docs
API playgroundTry for free, no card

Search company profiles

Qitan Technology

Full company profile

uuid00023om

Namestring
Qitan Technology
Legal namestring
Qitan Technology
Websiteurl
qitantech.com
Company typeenum
Private
Founded yearint
2016
Short descriptiontext

Qitan Technology is a Chengdu-based biotech that develops and manufactures nanopore-based gene sequencers — including China's first domestically produced nanopore platform (QNome) — and sells them to Chinese research laboratories, academic institutions, and clinical genomics customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersChengdu, China
HQ citystring
Chengdu
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nanopore gene sequencer, DNA sequencing instruments, genomics laboratory equipment, next-generation sequencing, life sciences research tools
Industry1 code
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
Product category
Genomics Sequencing Instruments
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Gene sequencing hardware sales
TypeHardware Sales
Description

Qitan Technology generates revenue through the sale of nanopore gene sequencers. The company develops and manufactures fourth-generation sequencing equipment, with plans for mass production of domestically developed nanopore gene sequencers targeting laboratories and research institutions.

yicaiglobal.com
2R&D and product development services
TypeProfessional Services
Description

The company engages in R&D and product development activities for nanopore gene sequencing technology, which may include professional services, custom development, or technology licensing components.

equalocean.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Qitan Technology develops and manufactures nanopore gene sequencers for DNA/RNA sequencing applications. The company offers its QNome nanopore sequencing platform along with a fourth-generation gene sequencer designed to be competitively priced to reduce sequencing costs for laboratories and research institutions. As China's first domestically developed nanopore gene sequencer manufacturer, the company is positioned in the next-generation gene sequencing market.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Significantly reduce costs for laboratories through competitively priced fourth-generation gene sequencer
Product and service3 records
1QNome Nanopore Gene Sequencing Platform
CategoryGene Sequencing Instruments
Description

The QNome nanopore gene sequencing platform developed by Qitan Technology for DNA/RNA sequencing applications in research and clinical laboratory settings.

2Nanopore Gene Sequencer (First Domestically Developed)
CategoryGene Sequencing Instruments
Description

China's first domestically developed nanopore gene sequencer, utilizing nanopore-based DNA sequencing technology for genetic analysis. Targeted at laboratories and research institutions for genomic research and clinical applications.

3Fourth-Generation Gene Sequencer
CategoryGene Sequencing Instruments
Description

Next-generation nanopore gene sequencer designed to be competitively priced and significantly reduce costs for laboratories requiring gene sequencing equipment.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Peers10 records
TypeDirect peer
Description

Global pioneer and leader in nanopore-based sequencing (MinION, GridION, PromethION). Most directly comparable to Qitan as the original nanopore sequencing company targeting similar research and clinical use cases.

TypeDirect peer
Description

China-based genomics giant with significant domestic sequencing instrument manufacturing (including via MGI Tech) and large installed base of sequencers across Chinese research and clinical labs—Qitan's most direct domestic rival.

TypeDirect peer
Description

BGI-affiliate developing DNBSEQ sequencing platforms; competes head-to-head in the Chinese sequencer market with Qitan on cost and performance for laboratory customers.

TypeBroad incumbent
Description

Dominant short-read sequencing incumbent with global installed base; competes in the broader DNA sequencing market Qitan addresses and sets the benchmark for performance and pricing pressure.

TypeBroad incumbent
Description

Long-read sequencing competitor (HiFi reads via SMRT technology) competing with nanopore in high-accuracy long-read applications such as whole-genome assembly and clinical research.

TypeEmerging player
Description

Emerging sequencing platform developer (AVITI) targeting lower-cost benchtop sequencers; competes on price-performance for the same research-lab customer base Qitan targets.

TypeEmerging player
Description

Developer of the G4 benchtop sequencer, positioning as a low-cost alternative to Illumina in research settings—directly comparable to Qitan's cost-competitive laboratory sequencer strategy.

TypeBroad incumbent
Description

Life sciences tools giant offering sequencing through the Ion Torrent platform and adjacent genomic analysis instruments; broad incumbent with overlapping capabilities rather than a nanopore specialist.

TypeEmerging player
Description

Early-stage developer of a low-cost, benchtop electronic sequencing platform; niche overlap with Qitan on affordable sequencers for smaller laboratories.

TypeBroad incumbent
Description

Global diagnostics and sequencing player with nanopore-related investments and clinical sequencing ambitions; broader portfolio competitor with relevant sequencing overlap.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Qitan Technology

Genomics Sequencing Instrumentsqitantech.com

Qitan Technology is a Chengdu-based biotech that develops and manufactures nanopore-based gene sequencers — including China's first domestically produced nanopore platform (QNome) — and sells them to Chinese research laboratories, academic institutions, and clinical genomics customers.

Qitan Technology firmographics

Firmographics
Name
Qitan Technology
Legal name
Qitan Technology
Website
https://qitantech.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
Qitan Technology is a Chengdu-based biotech that develops and manufactures nanopore-based gene sequencers — including China's first domestically produced nanopore platform (QNome) — and sells them to Chinese research laboratories, academic institutions, and clinical genomics customers.
Ownership category
akta.pro rank

Qitan Technology industry classification

Industry
Product category
Genomics Sequencing Instruments
akta.pro industry
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)

Keywords

  • Nanopore gene sequencer
  • DNA sequencing instruments
  • Genomics laboratory equipment
  • Next-generation sequencing
  • Life sciences research tools

Where Qitan Technology is headquartered

Location

Headquarters

HQ city
Chengdu
HQ country
China
HQ region
Asia

Offices1 record

Markets served

Qitan Technology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

  1. Gene sequencing hardware sales: Qitan Technology generates revenue through the sale of nanopore gene sequencers. The company develops and manufactures fourth-generation sequencing equipment, with plans for mass production of domestically developed nanopore gene sequencers targeting laboratories and research institutions.
  2. R&D and product development services: The company engages in R&D and product development activities for nanopore gene sequencing technology, which may include professional services, custom development, or technology licensing components.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Qitan Technology product offering

Product offering

Core offering

Qitan Technology develops and manufactures nanopore gene sequencers for DNA/RNA sequencing applications. The company offers its QNome nanopore sequencing platform along with a fourth-generation gene sequencer designed to be competitively priced to reduce sequencing costs for laboratories and research institutions. As China's first domestically developed nanopore gene sequencer manufacturer, the company is positioned in the next-generation gene sequencing market.

Differentiator

Problem solved

Functional benefit

Products and services

  • QNome Nanopore Gene Sequencing Platform The QNome nanopore gene sequencing platform developed by Qitan Technology for DNA/RNA sequencing applications in research and clinical laboratory settings.
  • Nanopore Gene Sequencer (First Domestically Developed) China's first domestically developed nanopore gene sequencer, utilizing nanopore-based DNA sequencing technology for genetic analysis. Targeted at laboratories and research institutions for genomic research and clinical applications.
  • Fourth-Generation Gene Sequencer Next-generation nanopore gene sequencer designed to be competitively priced and significantly reduce costs for laboratories requiring gene sequencing equipment.

Quantifiable outcome

  • Significantly reduce costs for laboratories through competitively priced fourth-generation gene sequencer

Companies that use Qitan Technology

Customer profile

Segments1 record

Ideal customer profiles1 record

Qitan Technology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Qitan Technology partnerships and signals

Strategic signal

Scale indicators5 records

Qitan Technology competitors and assessment

Company assessment

Direct peers

  • Oxford Nanopore Technologies: Global pioneer and leader in nanopore-based sequencing (MinION, GridION, PromethION). Most directly comparable to Qitan as the original nanopore sequencing company targeting similar research and clinical use cases.
  • BGI Group: China-based genomics giant with significant domestic sequencing instrument manufacturing (including via MGI Tech) and large installed base of sequencers across Chinese research and clinical labs—Qitan's most direct domestic rival.
  • MGI Tech: BGI-affiliate developing DNBSEQ sequencing platforms; competes head-to-head in the Chinese sequencer market with Qitan on cost and performance for laboratory customers.

Broad incumbents

  • Illumina: Dominant short-read sequencing incumbent with global installed base; competes in the broader DNA sequencing market Qitan addresses and sets the benchmark for performance and pricing pressure.
  • Pacific Biosciences: Long-read sequencing competitor (HiFi reads via SMRT technology) competing with nanopore in high-accuracy long-read applications such as whole-genome assembly and clinical research.
  • Thermo Fisher Scientific: Life sciences tools giant offering sequencing through the Ion Torrent platform and adjacent genomic analysis instruments; broad incumbent with overlapping capabilities rather than a nanopore specialist.
  • Roche (Genentech Diagnostics / Sequencing): Global diagnostics and sequencing player with nanopore-related investments and clinical sequencing ambitions; broader portfolio competitor with relevant sequencing overlap.

Emerging players

  • Element Biosciences: Emerging sequencing platform developer (AVITI) targeting lower-cost benchtop sequencers; competes on price-performance for the same research-lab customer base Qitan targets.
  • Singular Genomics: Developer of the G4 benchtop sequencer, positioning as a low-cost alternative to Illumina in research settings—directly comparable to Qitan's cost-competitive laboratory sequencer strategy.
  • GenapSys: Early-stage developer of a low-cost, benchtop electronic sequencing platform; niche overlap with Qitan on affordable sequencers for smaller laboratories.

Market position

Customer concentration

Qitan Technology social profiles

Digital presence

Qitan Technology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Qitan Technology leadership team

Management profile

Number of profiles

Profiles4 records

Qitan Technology funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Qitan Technology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qitan Technology

What does Qitan Technology do?

Qitan Technology develops and manufactures nanopore gene sequencers for DNA/RNA sequencing applications. The company offers its QNome nanopore sequencing platform along with a fourth-generation gene sequencer designed to be competitively priced to reduce sequencing costs for laboratories and research institutions. As China's first domestically developed nanopore gene sequencer manufacturer, the company is positioned in the next-generation gene sequencing market.

Is Qitan Technology a public or private company?

Qitan Technology is a private company. It is classified as venture growth investor backed and is currently operating.

When was Qitan Technology founded?

Qitan Technology was founded in 2016. It employs 51 to 100 people.

Where is Qitan Technology based?

Qitan Technology is headquartered in Chengdu, China, in the Asia region.

How does Qitan Technology make money?

Two revenue lines are on record. Gene sequencing hardware sales are the primary driver. The others are R&D and product development services.

Who are Qitan Technology's main competitors?

Direct peers on record are Oxford Nanopore Technologies, BGI Group and MGI Tech. Broad incumbents are Illumina, Pacific Biosciences, Thermo Fisher Scientific and Roche (Genentech Diagnostics / Sequencing). Emerging players are Element Biosciences, Singular Genomics and GenapSys.

Does Qitan Technology have an API?

No public API is recorded for Qitan Technology.

What industry is Qitan Technology in?

Qitan Technology's product category is Genomics Sequencing Instruments. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TechRoundTop Medtech Startups In ChinaChina's medtech sector has become one of the world's fastest-growing, driven by advances in AI diagnostics, medical imaging, surgical robotics, digital health, genomics and smart medical devices, with over 360 innovative medical devices approved by China's National Medical Products Administration between 2014 and 2025. The article profiles eight leading Chinese medtech startups including WeDoctor, Ping An Good Doctor, DeepWise, Yitu Healthcare, LinkDoc Technology, NeuroXess, QitanTech and GeneMind, which collectively cover telemedicine, AI-powered medical imaging, clinical data analytics, brain-computer interfaces and next-generation genomic sequencing. These companies are addressing critical healthcare needs driven by China's population of 1.4 billion, an aging demographic, rising chronic diseases and uneven distribution of healthcare resources between urban and rural areas.医药魔方-致力于数据赋能医药创新,助力高效决策与数智化转型Qichan Technology completes nearly 100 million RMB C+ round financing - Medical News - ByDrug - One-stop medical resource sharing center - Medical CubeQitan Technology completed a nearly 100 million RMB C+ round of financing on December 28, 2023, with investments from Ceyuan Capital and Chengdu Biocity Fund. The funding is designated to support the company's product technology research and development, capacity expansion, and market development for its nanopore gene sequencing solutions. This investment aims to help Qitan Technology further commercialize its domestic sequencing platforms and reduce reliance on imported technology.Labiotech.euThe biggest private biotech investments in December 2022A roundup of the largest private biotech investments in December 2022 identifies multiple companies across healthcare and industrial biotechnology sectors that secured significant funding rounds globally. Apogee Therapeutics led U.S. healthcare biotech with a $149 million Series B round, while Qitan Technology topped the Asia-Pacific industrial biotech rankings with a $100 million Series C round to develop a nanopore-based DNA sequencer. European companies also saw notable funding, including U.K.-based Pulmocide's $52 million Series C and Sweden's EnginZyme's $22.3 million Series B round.PedailyFirst release | Qitan Technology completes 700 million yuan Series C financing, the largest single financing in the life sciences field this year.Chengdu Qitan Technology Co., Ltd. completed a 700 million yuan Series C financing round led by Meituan, with continued investment from Huagai Capital and Boyuan Capital, marking the largest single financing in China's life sciences sector this year. The company plans to use the funds to accelerate the launch of medium and high-throughput sequencing platforms and expand its commercial territory, leveraging its newly established production base in Chengdu. This funding supports Qitan Technology's goal to further localize its supply chain and increase market share in the rapidly growing domestic gene sequencing industry.EqualOceanQitan technology has raised more than 400 million yuan in round B financing, and is jointly led by hillhood venture capital and CDH VGCQitan Technology announced the completion of its Round B financing, raising over 400 million RMB jointly led by Hillhead Venture Capital and CDH VGC. The company focuses on the independent research, development, and manufacturing of nanopore single-molecule gene sequencers and related technologies. This funding supports plans for mass production within the year, positioning Qitan as a key player in breaking foreign monopolies in fourth-generation gene sequencing.